—SRE
— • —
$96.18
P/E
34.22
PEG
—
FCF Yield
—
Rev Growth YoY
+379.0% YoY
Gross Margin
—
Health Score
4/10
D/E Ratio
1.11
Confidence
LOW
Business Snapshot
The ticker and exchange identifiers are absent from this payload, which limits contextual background. Based on available financial data, this appears to be a company trading at $96.18 per share with a P/E ratio of 34.22x and a Price/Sales ratio of 5.32x, suggesting a growth-oriented business. Without market capitalisation data, a definitive cap-tier classification cannot be assigned.
Financial Health
**Score: 4/10** The balance sheet presents a mixed picture. Debt/equity stands at 1.11x, which is moderate but warrants monitoring, while the current ratio of 1.59x suggests the company can cover near-term obligations — a modestly reassuring liquidity signal...
Risk Assessment
- **DATA QUALITY:** Net margin of 1,547% combined with earnings growth of -3,736% strongly implies non-recurring distortions; reported figures cannot be taken at face value. - **VALUATION:** P/E of 34.22x is elevated versus the sector average of 25x, leaving limited margin of safety if growth disappoints. - **CASH FLOW:** Free cash flow is unavailable, making it impossible to confirm whether headline profitability translates to real economic value. - **TECHNICALS:** A death cross (50-day MA crossing below 200-day MA) is in effect, with the price sitting below both moving averages — a bearish structural signal. - **TRANSPARENCY:** TTM Revenue, TTM Net Income, gross margin, and EV/EBITDA are all absent, creating meaningful blind spots in fundamental analysis. ---...